272 related articles for article (PubMed ID: 25820617)
1. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
Nimczick M; Decker M
ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
[TBL] [Abstract][Full Text] [Related]
3. Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor.
Han S; Chen JJ; Chen JZ
Mini Rev Med Chem; 2014 May; 14(5):426-43. PubMed ID: 24766386
[TBL] [Abstract][Full Text] [Related]
4. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.
Galaj E; Xi ZX
CNS Drugs; 2019 Oct; 33(10):1001-1030. PubMed ID: 31549358
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.
Huang G; Pemp D; Stadtmüller P; Nimczick M; Heilmann J; Decker M
Bioorg Med Chem Lett; 2014 Sep; 24(17):4209-14. PubMed ID: 25096297
[TBL] [Abstract][Full Text] [Related]
6. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
González-Naranjo P; Pérez-Macias N; Campillo NE; Pérez C; Arán VJ; Girón R; Sánchez-Robles E; Martín MI; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Páez JA
Eur J Med Chem; 2014 Feb; 73():56-72. PubMed ID: 24378710
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
9. Translational potential of allosteric modulators targeting the cannabinoid CB
Lu D; Immadi SS; Wu Z; Kendall DA
Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554
[TBL] [Abstract][Full Text] [Related]
10. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products.
An D; Peigneur S; Hendrickx LA; Tytgat J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32709050
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
12. Signaling molecules targeting cannabinoid receptors: Hemopressin and related peptides.
Wei F; Zhao L; Jing Y
Neuropeptides; 2020 Feb; 79():101998. PubMed ID: 31831183
[TBL] [Abstract][Full Text] [Related]
13. Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.
Mallipeddi S; Janero DR; Zvonok N; Makriyannis A
Biochem Pharmacol; 2017 Mar; 128():1-11. PubMed ID: 27890725
[TBL] [Abstract][Full Text] [Related]
14. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids and Their Pharmacological Actions.
Pertwee RG
Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
[TBL] [Abstract][Full Text] [Related]
16. Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations.
Jung SW; Cho AE; Yu W
Sci Rep; 2018 Sep; 8(1):13787. PubMed ID: 30213978
[TBL] [Abstract][Full Text] [Related]
17. One for the Price of Two…Are Bivalent Ligands Targeting Cannabinoid Receptor Dimers Capable of Simultaneously Binding to both Receptors?
Glass M; Govindpani K; Furkert DP; Hurst DP; Reggio PH; Flanagan JU
Trends Pharmacol Sci; 2016 May; 37(5):353-363. PubMed ID: 26917061
[TBL] [Abstract][Full Text] [Related]
18. Structure-kinetic relationship studies of cannabinoid CB
Soethoudt M; Hoorens MWH; Doelman W; Martella A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2018 Jun; 152():129-142. PubMed ID: 29574067
[TBL] [Abstract][Full Text] [Related]
19. Targeting the endocannabinoid system: future therapeutic strategies.
Aizpurua-Olaizola O; Elezgarai I; Rico-Barrio I; Zarandona I; Etxebarria N; Usobiaga A
Drug Discov Today; 2017 Jan; 22(1):105-110. PubMed ID: 27554802
[TBL] [Abstract][Full Text] [Related]
20. New cannabinoid receptor antagonists as pharmacological tool.
González-Naranjo P; Pérez C; Girón R; Sánchez-Robles EM; Martín-Fontelles MI; Carrillo-López N; Martín-Vírgala J; Naves M; Campillo NE; Páez JA
Bioorg Med Chem; 2020 Oct; 28(19):115672. PubMed ID: 32912440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
